Tariffs and federal research “uncertainty” are forcing a Peninsula company to lay off workers at headquarters and cut other ...

Bernstein analyst Eve Burstein lowered the firm’s price target on PacBio (PACB) to $1.50 from $2 and keeps an Outperform rating on the shares.

By Sneha S K (Reuters) -Gene sequencing equipment maker PacBio plans to cut around 120 jobs and lower expenses due to fresh ...

Shares of PacBio (PACB) traded nearly 20% higher on Wednesday after the company said it is executing a plan, including job ...

Rady study uses PacBio long-read sequencing for RFX3 variant in adolescent patient with autism, showcasing clinical genomics ...

PacBio reaffirms 2025 revenue outlook and unveils cost-cutting measures as Vega system demand grows and Revio usage meets ...

Tariffs and federal research “uncertainty” are forcing this Menlo Park biotech company to lay off workers at headquarters and ...

Pacific Biosciences is reducing both headcount and spending across its DNA sequencing business, in the face of escalating global tariffs and threats to federal biomedical research grants. | Looking to ...

A major new initiative was launched on Tuesday (15 April) by the Wellcome Sanger Institute in collaboration with Pacific ...

Our preliminary revenue for the first quarter met our expectations despite impacts from ongoing uncertainty in NIH funding in the United States and broader economic headwinds affecting the industry.

In a report released yesterday, Eve Burstein from Bernstein maintained a Buy rating on Pacific Biosciences (PACB – Research Report), with a ...

PacBio to Cut Jobs, Lower Spending Over NIH Funding Cuts and Tariffs By Sneha S K (Reuters) -Gene sequencing equipment maker PacBio plans to cut around 120 jobs and lower expenses due to fresh ...